Data plays a key role in economic modeling and forecasting for rare disease treatment distribution. Here’s how.
Using Data for Better Forecasting in the Pharmaceutical Industry Read More »
U.S. payers consider several factors when evaluating specialty therapies for coverage — all of which benefit from better data.
What US Payers Evaluate for Specialty Therapy Coverage Read More »
Third-party logistics providers can be a rich source of insight. Here are three things their data can help you understand.
3 Insights You Can Learn From Third-Party Logistics Providers’ Data Read More »
Payers prefer to back data-based, evidence-driven therapies. Here’s the information they need to understand value.
Do Payers Have Data to Assess Rare Disease Therapies? Read More »
Rare disease communities and their members offer a valuable source of qualitative data to other patients and healthcare providers.
Engaging Rare Disease Communities for Qualitative Data Read More »
Prior authorization can be improved by streamlining data collection and communication. Here’s how the Hub helps.
Using the Hub to Improve the Prior Authorization Process Read More »
Key opinion leaders (KOLs) drive understanding and knowledge. Here’s how to connect with the top minds in rare diseases.
Tips for Working With Key Opinion Leaders in Rare Diseases Read More »
Data insights in specialty drug distribution drives better decision making. Here’s how the Hub provides key information.
Unpacking Data Insights to Understand How Enrollment Hub is Performing Read More »
Is your pharmaceutical market access strategy meeting its goals? Here’s what to track.
Essential KPIs for Your Pharmaceutical Market Access Strategy Read More »
Complex U.S. payer systems in healthcare don’t lend themselves easily to economic models. Here’s how tech can help.
Modeling Complex Payer Systems in Specialty Pharmaceutical Therapies Read More »